CYP4F11 promotes lung cancer progression through the miR-195/ME2 pathway

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Cytochrome P450 enzyme CYP4F11 is overexpressed in non-small cell lung cancer (NSCLC), correlating with poor patient outcomes.
• CYP4F11 plays a role in fatty acid and drug metabolism, suggesting its involvement in cancer progression.

Purpose of the Study:

• To investigate the role of CYP4F11 as a prognostic biomarker and therapeutic target in NSCLC.
• To elucidate the molecular mechanisms underlying CYP4F11's function in NSCLC progression.

Main Methods:

• Integrated analysis of TCGA/GEO datasets and immunohistochemistry on 235 NSCLC specimens.
• In vitro functional studies (cell proliferation, clonogenicity, migration) and in vivo xenograft models.
• Mechanistic investigation involving miR-195, mitochondrial malic enzyme 2 (ME2), and metabolomic analysis.

Main Results:

• CYP4F11 was validated as a novel prognostic biomarker for NSCLC.
• CYP4F11 knockdown inhibited NSCLC cell proliferation, clonogenicity, and migration in vitro and suppressed tumor growth in vivo.
• CYP4F11 was identified as a direct target of miR-195, and its suppression led to ME2 degradation, disrupting mitochondrial malate metabolism and promoting oncogenesis.

Conclusions:

• The CYP4F11/miR-195/ME2 regulatory axis is crucial for NSCLC progression.
• CYP4F11 is a potential prognostic indicator and therapeutic target for NSCLC by modulating cancer cell metabolism.